In particular, the administration of metformin, which has been proposed as a repurposed drug for cancer treatment [68, 69, 73, 74], alleviates IL-1RA-promoted OSCC malignancy through EGFR/JNK signaling and SOX2 expression. This evidence concerns the gene EGFR and cancer.